Evolv Q3 Revenue Up 10% to $47.3M, ARR Climbs 20% as 2026 Outlook Tightens
EVLV is trading near its 52-week low of $4.02 (10% above the low).
Summary
Evolv reported Q3 2026 revenue of $47.3 million, up 10% from $42.9 million a year ago, with ARR at $140.5 million, up 20%. Growth decelerated sharply from the 34% posted in Q2, which management attributed to a tough comparison against last year's largest-ever contract. The GAAP net loss widened to $15.6 million, or $0.09 per share, from $1.8 million a year ago, largely on a $4.8 million swing in non-recurring legal and regulatory costs and the absence of last year's $7.5 million earn-out fair-value gain; adjusted EBITDA slipped to $4.7 million from $5.1 million. Management nudged 2026 revenue guidance to $182-$185 million from $180-$185 million and Adjusted EBITDA to $15.5-$16.5 million from $15-$16 million, while keeping ending ARR at $148-$150 million. Cash and marketable securities stood at $66.9 million at September 30, and free cash flow turned positive at $3.2 million versus negative $11.5 million a year ago. The 4:30 p.m. ET call will be the venue for questions on the deceleration and the SEC investigation referenced in the filing language.
At the time of this announcement, EVLV was trading at $4.44 on NASDAQ in the Technology sector, with a market capitalization of approximately $804.2M. The 52-week trading range was $4.02 to $7.48. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.